Seeking Alpha

ImmunoGen signs another licensing agreement with Novartis

  • Novartis (NVS) has signed a third agreement this year to license ImmunoGen's (IMGN) antibody-drug conjugate (ADC) technology to develop cancer therapies.
  • This is the fifth license that ImmunoGen has signed with a major healthcare company in 2013, with Eli Lilly and Amgen also using the tech.
  • The terms of the latest Novartis agreement are consistent with a license announced last month. Under a 2010 agreement, the Swiss giant pays an upfront fee to ImmunoGen for each permit, milestone payments of up to $200M, and any royalties on sales.
  • Surprisingly, Immunogen's shares are -4.2%. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)